Literature DB >> 10451780

Achieving an optimal outcome in the treatment of infections. The role of clinical pharmacokinetics and pharmacodynamics of antimicrobials.

R C Li1, M Zhu, J J Schentag.   

Abstract

Over the past few decades, the importance of applying pharmacokinetic principles to the design of drug regimens has been increasingly recognised by clinicians. From the perspective of antimicrobial chemotherapy, an improvement in clinical outcome and/or a reduction in toxicity are of primary interest. Before application of these pharmacokinetic theories can be effective, the interrelationships between antimicrobial, pathogen and host factors must be clearly defined. Information regarding the pharmacokinetics of the antimicrobial and the quantification of pathogen susceptibility is required. Even though susceptibility end-points such as minimum inhibitory concentration (MIC) and minimum bactericidal concentration are widely employed, they do not provide any information on dynamic changes of bacterial densities. In this regard, time-kill studies can provide more basic knowledge of the complex bacterial responses to the antimicrobial. Better prediction of these responses can be afforded by the use of mathematical models. More recently, various surrogate end-points employing a combination of suitable pharmacokinetic parameters and susceptibility data, for example the ratio of peak concentration to MIC, the area under the concentration-time curve above the MIC (AUC > MIC), the time above the MIC, or the area under the inhibitory curve (AUIC), have been suggested for better prediction of the activity of different classes of antimicrobials. To allow more extensive investigations of the contribution of pharmacokinetics to the pharmacodynamics of antimicrobials, various in vitro kinetic models have been developed. However, certain limitations exist, and it is necessary to avoid over-interpretation of the data generated by these models. Two important microbial dynamic responses, postantibiotic effect and resistance selection, must be further explored before the full impact of pharmacokinetics on antimicrobial chemotherapy can be depicted. The present paper aims at discussing all the relevant factors and provides some pertinent information on the use of pharmacokinetic-pharmacodynamic principles in antimicrobial therapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10451780     DOI: 10.2165/00003088-199937010-00001

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  74 in total

1.  Mathematical examination of dual individualization principles (I): Relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin.

Authors:  J J Schentag; D E Nix; M H Adelman
Journal:  DICP       Date:  1991-10

2.  Impact of pharmacokinetics on the postantibiotic effect exhibited by Pseudomonas aeruginosa following tobramycin exposure: application of an in-vitro model.

Authors:  Z Y Zhu; R C Li
Journal:  J Antimicrob Chemother       Date:  1998-07       Impact factor: 5.790

3.  Two compartment kinetic model with multiple artificial capillary units.

Authors:  J Blaser; B B Stone; S H Zinner
Journal:  J Antimicrob Chemother       Date:  1985-01       Impact factor: 5.790

4.  Impact of dosage regimens on the efficacy of piperacillin against Pseudomonas aeruginosa in neutropenic mice.

Authors:  J G Zhi; C H Nightingale; R Quintiliani
Journal:  J Pharm Sci       Date:  1988-11       Impact factor: 3.534

5.  Mathematical model for comparison of time-killing curves.

Authors:  F Guerillot; G Carret; J P Flandrois
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

Review 6.  Inactivation of antibiotics and the dissemination of resistance genes.

Authors:  J Davies
Journal:  Science       Date:  1994-04-15       Impact factor: 47.728

7.  The theory and relevance of continuous culture.

Authors:  P Gilbert
Journal:  J Antimicrob Chemother       Date:  1985-01       Impact factor: 5.790

8.  Once versus thrice daily gentamicin in patients with serious infections.

Authors:  J M Prins; H R Büller; E J Kuijper; R A Tange; P Speelman
Journal:  Lancet       Date:  1993-02-06       Impact factor: 79.321

9.  Performance of the fractional maximal effect method: comparative interaction studies of ciprofloxacin and protein synthesis inhibitors.

Authors:  R C Li; D E Nix; J J Schentag
Journal:  J Chemother       Date:  1996-02       Impact factor: 1.714

10.  Assessment of effects of protein binding on daptomycin and vancomycin killing of Staphylococcus aureus by using an in vitro pharmacodynamic model.

Authors:  M W Garrison; K Vance-Bryan; T A Larson; J P Toscano; J C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  1990-10       Impact factor: 5.191

View more
  19 in total

1.  Activity of LY333328 in experimental meningitis caused by a Streptococcus pneumoniae strain susceptible to penicillin.

Authors:  J Gerber; A Smirnov; A Wellmer; J Ragheb; J Prange; E Schütz; K Wettich; S Kalich; R Nau
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

2.  Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers.

Authors:  H Stass; M F Böttcher; K Ochmann
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 3.  Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC.

Authors:  Markus Mueller; Amparo de la Peña; Hartmut Derendorf
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

4.  Pharmacokinetics of ciprofloxacin as a tool to optimise dosage schedules in community patients.

Authors:  M Dolores Sánchez Navarro; Carlos Coloma Milano; Aránzazu Zarzuelo Castañeda; M Luisa Sayalero Marinero; Amparo Sánchez-Navarro
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 5.  Pharmacokinetic considerations in the eradication of Helicobacter pylori.

Authors:  U Klotz
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

Review 6.  Pharmacokinetic factors in the modern drug treatment of tuberculosis.

Authors:  J G Douglas; M J McLeod
Journal:  Clin Pharmacokinet       Date:  1999-08       Impact factor: 6.447

7.  A Diffusion-Based and Dynamic 3D-Printed Device That Enables Parallel in Vitro Pharmacokinetic Profiling of Molecules.

Authors:  Sarah Y Lockwood; Jayda E Meisel; Frederick J Monsma; Dana M Spence
Journal:  Anal Chem       Date:  2016-01-15       Impact factor: 6.986

8.  Nitric oxide releasing nanoparticles are therapeutic for Staphylococcus aureus abscesses in a murine model of infection.

Authors:  George Han; Luis R Martinez; Mircea Radu Mihu; Adam J Friedman; Joel M Friedman; Joshua D Nosanchuk
Journal:  PLoS One       Date:  2009-11-12       Impact factor: 3.240

Review 9.  Selecting antibacterials for outpatient parenteral antimicrobial therapy : pharmacokinetic-pharmacodynamic considerations.

Authors:  Richard S Slavik; Peter J Jewesson
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

10.  Analysis of daptomycin efficacy and breakpoint standards in a murine model of Enterococcus faecalis and Enterococcus faecium renal infection.

Authors:  Jeff Alder; Tongchaun Li; Donghui Yu; Larry Morton; Jared Silverman; Xi-Xian Zhang; Ian Critchley; Grace Thorne
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.